Esther Latres

US Patent:

7632503, Dec 15, 2009

Filed:

Feb 14, 2008

Appl. No.:

12/070213

Inventors:

Trevor Stitt - Ridgewood NJ, US
Esther Latres - New York NY, US
David J. Glass - Cortlandt Manor NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61K 38/00

US Classification:

4241581, 514 12

Abstract:

A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.

US Patent:

20050079558, Apr 14, 2005

Filed:

Aug 28, 2003

Appl. No.:

10/652928

Inventors:

Michele Pagano - New York NY, US
Esther Latres - New York NY, US

International Classification:

G01N033/574

US Classification:

435007230

Abstract:

The present invention relates to the discovery and characterization of activity of Fbp1, a substrate-targeting ubiquitin ligase subunit. The invention encompasses interactions between Fbp1 and its substrates, including Fbp5, β-Catenin, and IκBα. The invention also encompasses interactions between the Fbp1 isoform β-Trcp2 and its substrates, including Fbp5, b-Catenin, and IκBα. The present invention relates to screening assays that use Fbp1 and/or β-Trcp2 to identify potential therapeutic agents such as small molecules, compounds or derivatives which modulate Fbp1 and/or β-Trcp2 activity for the treatment of proliferative and differentiative disorders, including infertility, cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention also encompasses methods to diagnose and treat Fbp1-related infertility disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target Fbp1 and its substrates for the treatment of infertility.

US Patent:

20050251871, Nov 10, 2005

Filed:

Jul 30, 2003

Appl. No.:

10/632150

Inventors:

Michele Pagano - New York NY, US
Esther Latres - New York NY, US

International Classification:

C12Q001/68
A01K067/00
C07H021/04
C12N009/64

US Classification:

800008000, 435006000, 435069100, 435226000, 435320100, 435325000, 536023200

Abstract:

The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.

US Patent:

20090292004, Nov 26, 2009

Filed:

Jul 22, 2008

Appl. No.:

12/220178

Inventors:

Michele Pagano - New York NY, US
Esther Latres - New York NY, US

International Classification:

A61K 31/7105
C12Q 1/25
C12Q 1/02
G01N 33/567
C12Q 1/68

US Classification:

514 44 A, 435 4, 435 29, 435 72, 435 6

Abstract:

The present invention relates to the discovery and characterization of activity of Fbp1, a substrate-targeting ubiquitin ligase subunit. The invention encompasses interactions between Fbp1 and its substrates, including Fbp5, β-Catenin, and IκBα. The invention also encompasses interactions between the Fbp1 isoform β-Trcp2 and its substrates, including Fbp5, b-Catenin, and IκBα. The present invention relates to screening assays that use Fbp1 and/or β-Trcp2 to identify potential therapeutic agents such as small molecules, compounds or derivatives which modulate Fbp1 and/or β-Trcp2 activity for the treatment of proliferative and differentiative disorders, including infertility, cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention also encompasses methods to diagnose and treat Fbp1-related infertility disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target Fbp1 and its substrates for the treatment of infertility.

US Patent:

20110293630, Dec 1, 2011

Filed:

May 25, 2011

Appl. No.:

13/115170

Inventors:

Trevor Stitt - Ridgewood NJ, US
Esther Latres - New York NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395
A61P 21/00
C07K 16/22

US Classification:

4241581, 5303879

Abstract:

The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.

US Patent:

20130122007, May 16, 2013

Filed:

Nov 14, 2012

Appl. No.:

13/676233

Inventors:

Esther Latres - New York NY, US

Assignee:

REGENERON PHARMACEUTICALS, INC. - Tarrytown NY

International Classification:

A61K 39/395
C07K 16/46

US Classification:

4241361, 4241391, 5303873

Abstract:

The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.

US Patent:

6720181, Apr 13, 2004

Filed:

Aug 27, 1999

Appl. No.:

09/385219

Inventors:

Michele Pagano - New York NY
Esther Latres - New York NY

Assignee:

New York University - New York NY

International Classification:

C12N 500

US Classification:

435325, 4353201, 435 6, 514 231, 514 235

Abstract:

The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.

US Patent:

20210163583, Jun 3, 2021

Filed:

Jul 10, 2020

Appl. No.:

16/926481

Inventors:

- Tarrytown NY, US
Esther Latres - New York NY, US
Andrew J. Murphy - Tarrytown NY, US
George D. Yancopoulos - Tarrytown NY, US
Lori C. Morton - Tarrytown NY, US

International Classification:

C07K 16/22
A61K 39/395

Abstract:

The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with Growth and Differentiation Factor 8 (GDF8) binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.